Bacillus sp. DU-106 ameliorates type 2 diabetes by modulating gut microbiota in high-fat-fed and streptozotocin-induced mice

Abstract

Aims: Type 2 diabetes (T2D) is a chronic disease that manifests as endocrine and metabolic disorders that seriously threatening public health. This study aimed to investigate the effects of Bacillus sp. DU-106 on anti-diabetic effects and gut microbiota in C57BL/6J mice fed a high-fat diet and streptozotocin-induced T2D.Methods and Results: Bacillus sp. DU-106 was administered to model mice for eight consecutive weeks. Oral administration of Bacillus sp. DU-106 decreased food and water intake and alleviated body weight loss. Moreover, Bacillus sp. DU-106 imparted several health benefits to mice, including balanced blood glucose, alleviation of insulin resistance in T2D mice and an improvement in lipid metabolism. Furthermore, Bacillus sp. DU-106 protected against liver and pancreatic impairment.Additionally, Bacillus sp. DU-106 treatment reshaped intestinal flora by enhancing gut microbial diversity and enriching the abundance of certain functional bacteria. Conclusion:Collectively, these findings suggest that Bacillus sp. DU-106 can ameliorate T2D by regulating the gut microbiota.Significance and Impact of Study: Therefore, a novel probiotic, Bacillus sp. DU-106 may be a promising therapeutic agent for improving and alleviating T2D in mice.

Alleviation Syndrome of High-Cholesterol-Diet-Induced Hypercholesterolemia in Mice by Intervention with Lactiplantibacillus plantarum WLPL21 via Regulation of Cholesterol Metabolism and Transportation as Well as Gut Microbiota

“…Jing et al reported that the abundance of Allobaculum and Blautia was increased after the supplementation of Bacillus sp. DU-106 and metformin [31]. Indeed, LAB intervention for hypercholesterolemia resulted in the change in different species.…”

Lactobacillus paracaseiIMC 502 ameliorates type 2 diabetes by mediating gut microbiota–SCFA–hormone/inflammation pathway in mice

“…Eight comparable studies reported its significant and positive effects on glucose and lipid metabolic biomarkers based on the wellestablished male C57BL/6J HFD-and STZ-induced T2DM mice, such as FBG, HbA1c, insulin, HOMA-IR, AUC glucose , TC, TG, HDL and LDL (Supporting Information Table S5). [35][36][37][38][39][40][41][42] Although the effects of L. paracasei IMC 502 on HOMA-IR and TC were weaker than that of metformin, its positive effects on the other biomarkers were comparable to that of metformin, possibly suggesting that this probiotic has a potential to improve T2DM and may complement the pharmacological effects of other anti-T2DM medications.…”

Latilactobacillus sakei QC9 alleviates hyperglycaemia in high-fat diet and streptozotocin-induced type 2 diabetes mellitus mice via the microbiota–gut–liver axis

“…DU-106 was proven to alleviate T2DM by regulating the blood glucose balance and modifying the dysbiosis of the gut microbiota. 26 These findings indicate that probiotics act in a strainspecific manner on the intestinal flora structure and associated glucose metabolism signalling pathways to alleviate T2DM. Hence, using probiotics as adjunctive therapy is becoming a viable approach to relieving T2DM.…”